Gent

• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending
  2025-524278-40-00 6 Patients undergoing Fludarabine based lymphodepletion prior to CAR-T c
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients wi … Pending
  2025-524367-20-00 4 Adult patients with primary mitochondrial disease
• Shorter versus longer antibiotic treatment for serious urinary tract infections in men Pending
  2025-524703-76-00 5 Urinary tract infection with systemic involvement (UTI: definite, prob
• A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo Pending
  2025-524726-18-00 4 Non-Segmental Vitiligo (NSV)
• A multicentre, open-label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens … Pending
  2025-524765-24-00 5 Rabies infection/prophylaxis
• Phase 2a Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis Pending
  2025-524784-20-00 4 Recurrent Pericarditis
• ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole Pending
  2025-524995-53-00 6 Women with endometriosis undergoing IVF/ICSI
• An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Trial on the Effects of EA-230 on the Length of Hospit … Pending
  2025-525053-39-00 5 Coronary artery disease
• Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer Recruiting
  2025-522888-15-00 3 2026-05-27 Small Cell Lung Cancer
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting
  2025-523180-38-00 4 2026-05-21 Uncontrolled Moderate to Severe Eosinophilic Asthma
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting
  2025-522896-27-00 4 2026-05-11 Asthma
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i … Recruiting
  2024-511593-70-00 5 2026-04-27 Polyarticular-course juvenile idiopathic arthritis
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• A clinical study to test how safe and effective a new inhaled treatment (called L606) is for people with high blood pressure in the lungs du … Recruiting
  2024-517943-29-00 5 2026-04-21 Pulmonary Hypertension associated with interstitial lung disease (WHO
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• A Study in Pediatric Participants with Congenital Adrenal Hyperplasia Recruiting
  2024-519578-38-00 10 2026-03-30 Classic congenital adrenal hyperplasia

Showing 49–72 of 904 trials